ACTRN12605000366651进行中（未招募）3 期
A double-blind, dose-ranging study to determine the optimal dose of oral morphine or oxycodone needed to treat breakthrough pain for people on regular opioid in the palliative care setting
Repatriation General Hospital0 个研究点目标入组 138 人开始时间: 2005年9月13日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •English speaking, AKPS performance status of 100 to 30, Calculated creatinine clearance of > 20 ml/minVenous blood sample for creatinine level, Stable background oral opioid for the previous 4 days, Successfully using breakthrough doses, Physically able to complete study measures.
排除标准
- •Confusion, Uncontrolled nausea or vomiting, Suspected gastro-intestinal obstruction, Known or suspected hypersensitivity to morphine or oxycodone, Past history of substance misuse, Declines to participate.
研究者
相似试验
进行中（未招募）
1 期
A dose finding study of OligoG in patients with CF.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2018-000378-30-DEAlgiPharma AS168
进行中（未招募）
1 期
A dose finding study of OligoG in patients with CF.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2018-000378-30-PLAlgiPharma AS180
进行中（未招募）
1 期
A dose finding study of OligoG in patients with CF.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2018-000378-30-ATAlgiPharma AS168
进行中（未招募）
1 期
A dose finding study of OligoG in patients with CF.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2018-000378-30-GBAlgiPharma AS168
进行中（未招募）
1 期
A dose finding study of OligoG in patients with CF.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2018-000378-30-IEAlgiPharma AS168